The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Foznol 750 mg Oral Powder



Takeda Pharmaceuticals International AG Ireland BranchPA23211/002/005

Main Information

Trade NameFoznol 750 mg Oral Powder
Active SubstancesLanthanum carbonate hydrate
Dosage FormOral powder
Licence HolderTakeda Pharmaceuticals International AG Ireland Branch
Licence NumberPA23211/002/005

Group Information

ATC CodeV03AE Drugs for treatment of hyperkalemia and hyperphosphatemia
V03AE03 lanthanum carbonate

Status

License statusAuthorised
Licence Issued11/05/2012
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back